Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study

被引：2

作者：

Graff, J. N. ^{[1
]}

Burotto, M. ^{[2
]}

Fong, P. C. ^{[3
]}

Pook, D. ^{[4
]}

Zurawski, B. ^{[5
]}

Kopp, R. Manneh ^{[6
]}

Salinas, J. E. ^{[7
]}

Bylow, K. ^{[8
,9
]}

Kramer, G. ^{[10
]}

Ratta, R. ^{[11
]}

Kwiatkowski, M. ^{[12
]}

Retz, M. ^{[13
]}

Kwak, C. ^{[14
]}

Arija, J. A. Arranz ^{[15
]}

Gurney, H. P. ^{[16
]}

Matsubara, N. ^{[17
]}

Liang, L. W. ^{[18
]}

Todoric, J. ^{[18
]}

Imai, K. ^{[18
]}

Stenzl, A. ^{[19
]}

机构：

[1] OHSU Oregon Hlth Sci Univ, Hematol Oncol Dept, Portland, OR USA

[2] Bradford Hill Clin Ctr, Med Oncol Dept, Recoleta, Chile

[3] Auckland City Hosp, Med Oncol Dept, Auckland, New Zealand

[4] Monash Hlth, Monash Med Ctr, Oncol Dept, Clayton, Vic, Australia

[5] Prof Franciszek Lukaszczyk Oncol Ctr, Oncol, Bydgoszcz, Poland

[6] Sociedad Oncol & Hematol Cesar, Dept Med Oncol, Valledupar, Colombia

[7] Hosp Prov Cordoba, Oncol, Cordoba, Spain

[8] Froedtert Hosp, Med Oncol, Milwaukee, WI USA

[9] Med Coll Wisconsin, Milwaukee, WI USA

[10] Med Univ Vienna, Urol, Vienna, Austria

[11] Hop Foch, Dept Med Oncol, Suresnes, France

[12] Szpital Wojewodzki Mikolaja Kopernika, Oddzial Dzienny Chemioterapii, Koszalin, Poland

[13] Tech Univ Munich, Rechts Isar Med Ctr, Urol, Munich, Germany

[14] Seoul Natl Univ, Coll Med, Urol, Yeongeon Med Campus, Seoul, South Korea

[15] Hosp Gen Univ Gregorio Maranon, Med Oncol, Madrid, Spain

[16] Macquarie Univ, Med Oncol, Fac Med Hlth & Human Sci, Sydney, NSW, Australia

[17] Natl Canc Ctr Hosp East, Dept Med Oncol, Kashiwa, Chiba, Japan

[18] Merck Co Inc, Oncol, Rahway, NJ USA

[19] Univ Tubingen, Urol Dept, Crona Kliniken, Tubingen, Germany

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2721

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1771MO

引用

页码：S957 / S957

页数：1

共 50 条

[1] Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) versus placebo plus enza for metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-641
Graff, Julie Nicole
Burgents, Joseph
Liang, Li Wen
Stenzl, Arnulf
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[2] KEYNOTE-641: Phase III study of pembrolizumab (pembro) plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC)
Graff, J. N.
Burgents, J.
Liang, L. W.
Stenzl, A.
ANNALS OF ONCOLOGY, 2019, 30
[3] KEYNOTE-641: Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer
Graff, Julie N.
Liang, Li Wen
Kim, Jeri
Stenzl, Arnulf
FUTURE ONCOLOGY, 2021, 17 (23) : 3017 - 3026
[4] PHASE 3 TRIAL OF PEMBROLIZUMAB AND ENZALUTAMIDE VERSUS ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) (KEYNOTE-641)
Graff, Julie Nicole
Burgents, Joseph
Liang, Li Wen
Stenzl, Arnulf
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A210 - A210
[5] Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: phase 3 KEYNOTE-641 study
Graff, Julie Nicole
Burgents, Joseph
Liang, Li Wen
Stenzl, Arnulf
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[6] KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Petrylak, D. P.
Li, B.
Schloss, C.
Fizazi, K.
ANNALS OF ONCOLOGY, 2019, 30 : 351 - 351
[7] Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921
Petrylak, Daniel Peter
Shore, Neal D.
Bennamoun, Mostefa
Ratta, Raffaele
Piulats, Josep M.
Li, Ben
Schloss, Charles
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[8] Biomarker analysis of men with enzalutamide (enza)resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) plus enza in KEYNOTE-199
Graff, J. N.
Tagawa, S.
Hoimes, C.
Gerritsen, W.
Vaishampayan, U. N.
Elliott, T.
Hwang, C.
Ten Tije, A. J.
Omlin, A. G.
McDermott, R. S.
De Wit, R.
Qiu, P.
Poehlein, C.
Kim, J.
Suttner, L.
Cristescu, R.
Marton, M. J.
Schloss, C.
de Bono, J. S.
Antonarakis, E. S.
ANNALS OF ONCOLOGY, 2021, 32 : S383 - S383
[9] Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5
Graff, Julie Nicole
Antonarakis, Emmanuel S.
Hoimes, Christopher J.
Tagawa, Scott T.
Hwang, Clara
Kilari, Deepak
Ten Tije, A. J.
Omlin, Aurelius Gabriel
McDermott, Raymond S.
Vaishampayan, Ulka N.
Elliott, Anthony
Wu, Helen
Kim, Jeri
Schloss, Charles
De Bono, Johann S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[10] KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).
Hoimes, Christopher J.
Graff, Julie N.
Tagawa, Scott T.
Hwang, Clara
Kilari, Deepak
Ten Tije, A. J.
Omlin, Aurelius
McDermott, Raymond S.
Vaishampayan, Ulka N.
Elliott, Tony
Gerritsen, Winald R.
Wu, Haiyan
Kim, Jeri
Schloss, Charles
De Bono, Johann S.
Antonarakis, Emmanuel S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →